Table 3.
Association ofACEgene D/I polymorphism with onset of clinical symptoms of patients in months considering the cohorts toCFTRmutation
| Groups | ACEgenotype | ≤ 3 months | > 3 months | Total | X2 | p | X2 | p | OR (CI 5-95%) |
|---|---|---|---|---|---|---|---|---|---|
| Without taking CFTR mutation into account |
I/I |
38 |
28 |
66 |
0,880 |
0,644 |
0.012 |
0.9136 |
1.035 (0.555 - 1.931) |
| I/D |
44 |
37 |
81 |
0.473 |
0.492 |
0.808 (0.4396 -1.484) |
|||
| D/D |
15 |
8 |
23 |
0.723 |
0.395 |
1.486 (0.5937, 3.721) |
|||
| No identified CFTR mutation |
I/I |
13 |
6 |
19 |
1,685 |
0,431 |
0.825 |
0.364 |
1.806 (0.5017 -6.498) |
| I/D |
9 |
9 |
18 |
1.624 |
0.203 |
0.438 (0.122 - 1.576) |
|||
| D/D |
3 |
1 |
4 |
0.357 |
0.977 |
2.045 (0.194 - 21.58) |
|||
| One CFTR mutation identified class I, II or III |
I/I |
10 |
11 |
21 |
5,564 |
0,062 |
4.217 |
0.049 |
0.297 (0.084 – 0.995) |
| I/D |
14 |
6 |
20 |
0.521 |
0.471 |
1.167 (0.775 – 1.757) |
|||
| D/D |
8 |
1 |
9 |
2.951 |
0.097 |
5,667 (0,647 – 49,61) |
|||
| Two CFTR mutation identified class I, II and/or III | I/I |
15 |
11 |
26 |
0,599 | 1,026 | 0.773 |
0.379 |
1.527 (0.593 - 3.936) |
| I/D |
21 |
22 |
43 |
0.122 |
0.727 |
0.854 (0.352 - 2.072) |
|||
| D/D | 4 | 6 | 10 | 0.511 | 0.704 | 0.611 (0.158 - 2.358) |
Values below 0.05 for p denote clinical correlation between variables. OR - odds ratio, CI- confidence interval, ≤ − less than or equal to, > − greater, D - deleted allele, I - insertion allele. No identified mutation (44 patients) – patients without of identified mutation in classes I, II or III. One identified mutation (51 patients) – patient with one identified mutation in class I, II, or III. Two identified mutation (85 patients) – patient with two mutations in class I, II or III.